Bertrand Coiffier Selected Research

Rituximab (Mabthera)

1/2019	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
11/2018	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
8/2018	Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.
5/2018	Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes.
9/2017	Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.
8/2017	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.
8/2017	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
5/2017	Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
5/2017	Clinical development of CT-P10 and other biosimilar cancer therapeutics.
1/2017	Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bertrand Coiffier Research Topics

Disease

54	Lymphoma (Lymphomas) 08/2018 - 04/2002
42	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2020 - 01/2002
37	Neoplasms (Cancer) 10/2017 - 01/2003
33	Non-Hodgkin Lymphoma (Lymphosarcoma) 06/2018 - 01/2002
20	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 11/2018 - 06/2005
14	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 10/2017 - 03/2011
13	B-Cell Lymphoma (Lymphoma, B Cell) 09/2017 - 02/2002
11	Disease Progression 01/2017 - 05/2004
10	Neutropenia 08/2017 - 08/2009
10	Anemia 01/2016 - 10/2005
9	Thrombocytopenia (Thrombopenia) 01/2017 - 08/2009
9	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2015 - 10/2003
8	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2019 - 04/2004
7	Infections 01/2017 - 01/2010
6	T-Cell Lymphoma (Lymphoma, T Cell) 12/2017 - 04/2005
6	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 02/2013 - 02/2003
5	Hematologic Neoplasms (Hematological Malignancy) 08/2014 - 06/2005
4	Rheumatoid Arthritis 11/2018 - 07/2014
4	Cytopenia 01/2015 - 06/2002
3	Pneumonia (Pneumonitis) 01/2019 - 08/2011
3	Hodgkin Disease (Hodgkin's Disease) 10/2016 - 07/2004
3	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2014 - 11/2006
3	Hyperuricemia 04/2010 - 12/2003
3	Tumor Lysis Syndrome 04/2010 - 12/2003
3	Multiple Myeloma 12/2009 - 07/2004
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 12/2008 - 08/2003
2	Fatigue 01/2020 - 08/2013
2	Diarrhea 01/2019 - 10/2012
2	Lymphadenopathy 10/2017 - 01/2017
2	Febrile Neutropenia 01/2017 - 01/2009
2	Fever (Fevers) 01/2017 - 08/2011
2	Carcinoma (Carcinomatosis) 06/2016 - 06/2005
2	Nausea 04/2015 - 08/2011
2	Vomiting 04/2015 - 08/2011
2	Cardiovascular Diseases (Cardiovascular Disease) 04/2015 - 08/2014
2	Asthenia 12/2009 - 08/2009

Drug/Important Bio-Agent (IBA)

64	Rituximab (Mabthera)FDA Link 01/2019 - 01/2002
30	Cyclophosphamide (Cytoxan)FDA LinkGeneric 08/2017 - 01/2002
29	Vincristine (Oncovin)FDA LinkGeneric 08/2017 - 01/2002
28	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2017 - 01/2002
27	Prednisone (Sone)FDA LinkGeneric 08/2017 - 01/2002
19	Monoclonal AntibodiesIBA 09/2017 - 01/2002
9	romidepsin (FK228)FDA Link 12/2017 - 02/2012
8	Proteins (Proteins, Gene)FDA Link 12/2016 - 06/2003
6	Biosimilar PharmaceuticalsIBA 11/2018 - 07/2012
6	Pharmaceutical PreparationsIBA 01/2017 - 02/2002
6	Histone Deacetylase InhibitorsIBA 01/2017 - 01/2014
6	Etoposide (VP 16)FDA LinkGeneric 10/2016 - 11/2002
6	Immunoconjugates (Immunoconjugate)IBA 01/2016 - 04/2010
5	ofatumumab FDA Link 01/2017 - 02/2008
5	temsirolimus FDA Link 01/2015 - 08/2009
5	Bortezomib (Velcade)FDA Link 05/2013 - 08/2005
4	Lenalidomide (CC 5013)FDA Link 01/2020 - 01/2012
4	CT-P10IBA 11/2018 - 05/2017
4	AnthracyclinesIBA 05/2018 - 12/2007
4	Biomarkers (Surrogate Marker)IBA 01/2018 - 05/2013
4	Biological ProductsIBA 05/2017 - 07/2002
4	Bleomycin (Blenoxane)FDA LinkGeneric 10/2016 - 12/2003
4	TOR Serine-Threonine KinasesIBA 01/2015 - 08/2009
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2010 - 10/2002
4	Interleukin-10 (Interleukin 10)IBA 04/2010 - 05/2004
3	idelalisibIBA 01/2019 - 03/2014
3	pixantrone (BBR 2778)IBA 06/2018 - 07/2012
3	Hemoglobins (Hemoglobin)IBA 10/2017 - 10/2006
3	Chlorambucil (Leukeran)FDA Link 01/2017 - 03/2003
3	Prednisolone (Predate)FDA LinkGeneric 01/2015 - 07/2008
3	Ifosfamide FDA LinkGeneric 01/2015 - 09/2010
3	Vindesine (Vindesin)IBA 12/2014 - 12/2003
3	InterferonsIBA 01/2013 - 10/2006
3	epoetin betaIBA 11/2012 - 08/2003
3	Allopurinol (Remid)FDA LinkGeneric 04/2010 - 12/2003
3	CytokinesIBA 04/2010 - 05/2004
3	rasburicase (Elitek)FDA Link 04/2010 - 12/2003
3	AntigensIBA 05/2006 - 01/2002
2	abexinostatIBA 01/2017 - 04/2015
2	coltuximab ravtansineIBA 01/2016 - 01/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2014 - 04/2013
2	Brentuximab VedotinIBA 05/2014 - 05/2014
2	Inotuzumab OzogamicinIBA 02/2013 - 04/2010
2	HematinicsIBA 11/2012 - 10/2005
2	Methotrexate (Mexate)FDA LinkGeneric 08/2012 - 09/2010
2	10-propargyl-10-deazaaminopterin FDA Link 08/2012 - 03/2011
2	Anti-Bacterial Agents (Antibiotics)IBA 11/2011 - 02/2003
2	Erythropoietin FDA Link 01/2010 - 08/2003
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 07/2009 - 09/2007
2	Teniposide (VM 26)FDA Link 07/2008 - 10/2006
2	fludarabineIBA 04/2008 - 03/2003
2	HLA Antigens (Human Leukocyte Antigens)IBA 05/2007 - 10/2002

Therapy/Procedure

54	Therapeutics 01/2020 - 05/2002
50	Drug Therapy (Chemotherapy) 06/2016 - 01/2002
7	Stem Cell Transplantation 11/2013 - 05/2002
4	Salvage Therapy 01/2015 - 11/2002
4	Splenectomy 08/2014 - 06/2002
3	Intravenous Infusions 08/2017 - 08/2011
3	Radiotherapy 01/2017 - 03/2005
3	Aftercare (After-Treatment) 12/2008 - 02/2004
2	Induction Chemotherapy 01/2020 - 12/2003
2	Immunotherapy 01/2016 - 03/2005
2	Transplantation 11/2013 - 01/2013
2	VAP-cyclo protocol 10/2006 - 01/2002